JP2023535405A - 呼吸器疾患に関連する状態の処置および防止 - Google Patents

呼吸器疾患に関連する状態の処置および防止 Download PDF

Info

Publication number
JP2023535405A
JP2023535405A JP2023504251A JP2023504251A JP2023535405A JP 2023535405 A JP2023535405 A JP 2023535405A JP 2023504251 A JP2023504251 A JP 2023504251A JP 2023504251 A JP2023504251 A JP 2023504251A JP 2023535405 A JP2023535405 A JP 2023535405A
Authority
JP
Japan
Prior art keywords
composition
subject
disease
antigen
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535405A5 (cg-RX-API-DMAC10.html
Inventor
バラダラジャン,ナビン
リウ,シンリ
Original Assignee
ユニバーシティー オブ ヒューストン システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー オブ ヒューストン システム filed Critical ユニバーシティー オブ ヒューストン システム
Publication of JP2023535405A publication Critical patent/JP2023535405A/ja
Publication of JP2023535405A5 publication Critical patent/JP2023535405A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023504251A 2020-07-22 2021-07-22 呼吸器疾患に関連する状態の処置および防止 Pending JP2023535405A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063055165P 2020-07-22 2020-07-22
US63/055,165 2020-07-22
US202063060503P 2020-08-03 2020-08-03
US63/060,503 2020-08-03
US202063108980P 2020-11-03 2020-11-03
US63/108,980 2020-11-03
PCT/US2021/042684 WO2022020542A1 (en) 2020-07-22 2021-07-22 Treatment and prevention of conditions associated with respiratory diseases

Publications (2)

Publication Number Publication Date
JP2023535405A true JP2023535405A (ja) 2023-08-17
JP2023535405A5 JP2023535405A5 (cg-RX-API-DMAC10.html) 2025-04-17

Family

ID=79729865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504251A Pending JP2023535405A (ja) 2020-07-22 2021-07-22 呼吸器疾患に関連する状態の処置および防止

Country Status (5)

Country Link
US (1) US20230270845A1 (cg-RX-API-DMAC10.html)
EP (1) EP4185272A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023535405A (cg-RX-API-DMAC10.html)
CA (1) CA3186799A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022020542A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025504814A (ja) * 2022-01-21 2025-02-19 ユニバーシティー オブ ヒューストン システム 呼吸器疾患のための経鼻ワクチンおよび治療剤
CN114712304B (zh) * 2022-04-18 2024-03-12 深圳大学 海藻酸钠基复合水凝胶的制备方法
WO2025194158A1 (en) * 2024-03-15 2025-09-18 University Of Houston System Mucosal vaccines against respiratory syncytial virus
WO2025199149A1 (en) * 2024-03-18 2025-09-25 Cour Pharmaceuticals Development Company Inc. Sting agonism for antigen specific tolerance
CN120459057B (zh) * 2025-06-06 2026-04-14 上海大学 一种单核细胞搭载型产氧脂质体及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019518739A (ja) * 2016-05-16 2019-07-04 インフェクシャス ディズィーズ リサーチ インスティチュート Peg化リポソームおよび使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
EP3471778A4 (en) * 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES
KR101982710B1 (ko) * 2017-03-17 2019-05-28 주식회사 큐라티스 스팅 작용자를 포함하는 면역항원보강제 및 백신 조성물
TW202003032A (zh) * 2018-03-23 2020-01-16 美商科迪亞克生物科學公司 包含s t i n g 促效劑之胞外囊泡

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019518739A (ja) * 2016-05-16 2019-07-04 インフェクシャス ディズィーズ リサーチ インスティチュート Peg化リポソームおよび使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2", BIORXIV, JPN6025034859, 23 July 2020 (2020-07-23), ISSN: 0005670459 *
THER ADV VACCINES, vol. 1(4), JPN6025034860, 2013, pages 131 - 143, ISSN: 0005670458 *
VIRUSES, vol. 12, 254, JPN6025034861, 25 February 2020 (2020-02-25), pages 1 - 15, ISSN: 0005670457 *

Also Published As

Publication number Publication date
CA3186799A1 (en) 2022-01-27
US20230270845A1 (en) 2023-08-31
EP4185272A4 (en) 2025-01-22
EP4185272A1 (en) 2023-05-31
WO2022020542A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
US20250127879A1 (en) Newcastle disease viruses and uses thereof
Alameh et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
Li et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
An et al. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
US20230270845A1 (en) Treatment and prevention of conditions associated with respiratory diseases
US8809290B2 (en) Methods and compositions to generate and control the effector profile of T cells by simultaneous loading and activation of selected subsets of antigen presenting cells
US20180256655A1 (en) Newcastle Disease Viruses and Uses Thereof
Lee et al. A booster dose of Delta× Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
Cao et al. Inside-out assembly of viral antigens for the enhanced vaccination
Wang et al. IL-7 promotes mRNA vaccine-induced long-term immunity
Verma et al. Tailoring Tfh profiles enhances antibody persistence to a clade C HIV-1 vaccine in rhesus macaques
Giovannoni et al. Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy
US20250195638A1 (en) Treatment and prevention of conditions associated with respiratory diseases
Wen et al. A new mRNA antigen vaccine induces potent B and T cell responses and in vivo protection against SARS-CoV-2
Mathew et al. Nasal CD4+ tissue-resident memory T cells provide cross-protective immunity to influenza
JP7655566B2 (ja) シンドビスウイルスベクター及びアゴニストモノクローナル抗体を用いる腫瘍免疫療法
US20230233674A1 (en) Intranasal vaccines and therapeutics for respiratory diseases
Gorman et al. Collaboration between the Fab and Fc Contribute to Maximal Protection Against SARS-CoV-2 Following NVX-CoV2373 Subunit Vaccine with Matrix-M™ Vaccination
Qi¹ et al. Single-cell analysis of the adaptive immune response
Chen et al. Immunogenicity, Efficacy and Twelve-Month Storage Stability Studies of a Lyophilized Rabies mRNA Vaccine. Vaccines 2025, 13, 743
Fu et al. IL-7 promotes mRNA vaccine-induced long-term immunity
Slamanig Development of an intranasal SARS-CoV-2 vaccine
Abraş Assessment of Immune Potency of SARS-CoV-2 VLP Vaccine in Mice, Enhanced Through Different Adjuvants and Liposome Complexation
Davis-Porada Human Immune Memory to COVID-19 mRNA Vaccines
Daccache Stem-like CD8 T Cells are Essential for Cellular Immunity but Restrain Antibody Responses During Influenza Infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260525